adenosine monophosphate has been researched along with Atherosclerosis in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J; Li, Z; Luo, K; Peng, X; Wu, Q; Xu, X; Zhang, Y; Zhou, X | 1 |
| Chlopicki, S; Kutryb-Zajac, B; Lipinski, M; Rybakowska, I; Slominska, EM; Smolenski, RT; Toczek, M; Zabielska, M; Zukowska, P | 1 |
| He, S; Shi, W; Wang, L; Wang, X; Zhao, Y | 1 |
| Dovlatova, N; Espinosa, DI; Fox, SC; Glenn, JR; Gurney, M; Hartman, D; Heptinstall, S; Hermann, D; Johnson, A; Magnusson, O; Manolopoulos, P; May, JA; Stefansson, K; White, AE | 1 |
| Schrader, J | 1 |
| Eltzschig, HK; Robson, SC | 1 |
| Brandl, R; Deckmyn, H; Penz, SM; Reininger, AJ; Siess, W; Toth, O | 1 |
7 other study(ies) available for adenosine monophosphate and Atherosclerosis
| Article | Year |
|---|---|
Cyclic di-AMP Rescues
Topics: Adenosine Monophosphate; Alveolar Bone Loss; Animals; Atherosclerosis; Interleukin-6; Mice; Periodontitis; Porphyromonas gingivalis | 2023 |
Extracellular nucleotide catabolism in aortoiliac bifurcation of atherosclerotic ApoE/LDLr double knock out mice.
Topics: Adenosine; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Extracellular Space; Iliac Artery; Mice; Mice, Knockout; Nucleotides; Receptors, LDL | 2014 |
Nitric oxide synthesis-promoting effects of valsartan in human umbilical vein endothelial cells via the Akt/adenosine monophosphate-activated protein kinase/endothelial nitric oxide synthase pathway.
Topics: Adenosine Monophosphate; AMP-Activated Protein Kinases; Antihypertensive Agents; Atherosclerosis; Chromones; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Human Umbilical Vein Endothelial Cells; Humans; Morpholines; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Valsartan | 2017 |
DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease.
Topics: Acrylamides; Adenosine Monophosphate; Aspirin; Atherosclerosis; Blood Platelets; Cells, Cultured; Dinoprostone; Drug Interactions; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP3 Subtype; Receptors, Purinergic P2Y12; Sulfones | 2008 |
NT5E mutations and arterial calcifications.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Monophosphate; Alkaline Phosphatase; Animals; Anti-Inflammatory Agents; Atherosclerosis; Calcinosis; Fibroblasts; Gene Deletion; Humans; Hydrolysis; Mice; Mutation; Phenotype | 2011 |
NT5E mutations and arterial calcifications.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Monophosphate; Adenosine Triphosphate; Antigens, CD; Apyrase; Atherosclerosis; Calcinosis; Fibroblasts; Gene Deletion; Humans; Hydrolysis; Mutation; Phosphoric Diester Hydrolases; Pyrophosphatases | 2011 |
Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Antibodies, Monoclonal; Aspirin; Atherosclerosis; Blood Coagulation Tests; Blood Platelets; Carotid Stenosis; Dose-Response Relationship, Drug; Hemorheology; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Thrombosis; Time Factors; von Willebrand Factor | 2007 |